STADA announced the European launch of locally-manufactured Ximluci® (ranibizumab) biosimilar to Roche/Genentech’s Lucentis®. Ximluci® is indicated for the treatment of visual impairment in all Lucentis® adult indications.
Ximluci® is the first product developed through a collaboration between STADA and Xbrane, and represents Xbrane’s first commercial launch. Both companies are jointly responsible for development and manufacturing of Ximluci®, whilst STADA holds the marketing authorisations and commercial rights.
In January 2023, STADA and Xbrane announced that Ximluci® was granted marketing authorisation by the MHRA for UK supply.